Conference Reports for NATAP

Presented at the 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL) Taipei, Taiwan February 16-19, 2012 Back

DRUG INTERACTION PROFILE OF TELAPREVIR       Reported by Jules Levin 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL), Taipei, Taiwan, February 16-19, 2012   Varun Garg*1, Robert S Kauffman1, Maria Beumont2, Rolf van Heeswijk2 1Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA; 2Janssen Infectious Diseases BVBA, Beerse, Belgium